January 2026 - Scancell

Scancell Financial Year 2026 Interim Results

by chantal | Jan 29, 2026 | Investor Presentations, Investors, Presentations

H126: solid iSCIB1+ data underpins planned progress

by alex | Jan 29, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Results and Business Update

by chantal | Jan 29, 2026 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

FDA clears global Phase III trial for iSCIB1+

by alex | Jan 26, 2026 | Immunobody, iSCIB1+, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

by chantal | Jan 26, 2026 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

« Older Entries